Table I.

Survival and body weights of Swiss H mice exposed for 4 months to MCS, since birth, and treated with chemopreventive agents after weaning, until the end of the experiment (7 months)

Experimental group	Gender	Initial no. of mice	Surviving mice		Body weights (g)
			4 months	7 months	At weaning	4 months	7 months
Sham	M	33	33 (100 %)	31 (93.9%)	20.9±0.79	37.9±0.78	42.2±1.18
	F	31	31 (100%)	28 (90.3%)	19.3±0.86	34.4±0.74	38.0±1.27
MCS	M	34	34 (100%)	24 (70.6%)a	17.9±0.54a	29.4±0.65b	40.1±0.91
	F	38	34 (89.5%)	17 (44.7%)b	16.6±0.58c	23.5±0.96b	35.5±1.36
MCS + myo-inositol	M	34	31 (91.2%)	23 (67.6%)a	17.4±0.55b	27.8±0.91b	40.2±0.94
	F	37	33 (89.2%)	20 (54.1%)b	15.5±0.43b	23.6±0.90b	33.1±1.33a
MCS + SAHA	M	35	29 (82.9%)c	24 (68.6%)a	17.5±0.38b	23.3±0.82b,d	32.8±1.22b,d
	F	35	29 (82.9%)c	16 (45.7%)b	16.4±0.30a	22.4±0.77b	32.5±1.21b
MCS + bexarotene	M	35	33 (94.3%)	31 (88.6%)e	17.8±0.55a	27.1±0.68b	37.4±0.94
	F	40	37 (92.5%)	31 (77.5%)f	16.7±0.54c	24.0±0.92b	32.9±1.15a
MCS + pioglitazone	M	34	32 (94.1%)	32 (94.1%)f	16.7±0.32b	29.9±0.64b	40.6±1.03
	F	35	31 (88.6%)	31 (88.6%)d	15.8±0.41b	27.5±0.52b,d	36.4±0.86
MCS + pioglitazone + bexarotene	M	31	27 (87.1%)c	22 (71.0%)b	15.5±0.56b	27.6±1.20b	36.7±0.89b,f
	F	34	23 (67.6%)b	16 (47.1%)b	14.6±0.66b,e	26.0±1.20b	28.9±1.75b,f

Body weight data are means ± standard errors within each experimental group. M, male. F, female.

^a P < 0.01, as compared with sham-exposed mice of the same gender.

^b P < 0.001, as compared with sham-exposed mice of the same gender.

^c P < 0.05, as compared with sham-exposed mice of the same gender.

^d P < 0.001, as compared with MCS-exposed mice of the same gender.

^e P < 0.05, as compared with MCS-exposed mice of the same gender.

^f P < 0.01, as compared with MCS-exposed mice of the same gender.